Osteosarcoma Incidence and Survival Rates from 1973 to 2004: Data from the Surveillance, Epidemiology, and End Results Program, Cancer, vol.115, issue.7, pp.1531-1543, 2009. ,
, Key Statistics for Osteosarcoma, 2018.
Bone Cancer Incidence by Morphological Subtype: A Global Assessment, Cancer Causes Control, vol.26, issue.8, pp.1127-1139, 2015. ,
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success, J. Clin. Oncol, vol.33, issue.27, pp.3029-3035, 2015. ,
An Update on Chemotherapy for Osteosarcoma, Expert Opin. Pharmacother, vol.16, issue.18, pp.2727-2736, 2015. ,
Chemotherapeutic Adjuvant Treatment for Osteosarcoma: Where Do We Stand?, Eur. J. Cancer, vol.47, issue.16, pp.2431-2445, 2011. ,
Neoadjuvant Chemotherapy for Osteosarcoma of the Extremities with Metastases at Presentation: Recent Experience at the Rizzoli Institute in 57 Patients Treated with Cisplatin, Doxorubicin, and a High Dose of Methotrexate and, Ifosfamide. Ann. Oncol, vol.14, issue.7, pp.1126-1134, 2003. ,
Postmetastasis Survival in High-Grade Extremity Osteosarcoma: A Retrospective Analysis of Prognostic Factors in 126 Patients, J. Surg. Oncol, vol.117, issue.6, pp.1223-1231, 2018. ,
Increased Survival of Patients Aged 0?29 Years with Osteosarcoma: A Period Analysis, Cancer Med, vol.7, issue.8, pp.3652-3661, 1984. ,
Structural Requirements for Bisphosphonate Binding on Hydroxyapatite: NMR Study of Bisphosphonate Partial Esters, ACS Med. Chem. Lett, vol.6, issue.4, pp.397-401, 2015. ,
Targeted Delivery to Bone and Mineral Deposits Using Bisphosphonate Ligands, Adv. Drug Delivery Rev, vol.99, pp.12-27, 2016. ,
of Clinical Oncology Executive Summary of the Clinical Practice Guideline Update on the Role of Bone-Modifying Agents in Metastatic Breast Cancer, J. Clin. Oncol, vol.29, issue.9, pp.1221-1227, 2011. ,
Real-World Effectiveness of Osteoporosis Therapies for Fracture Reduction in Post-Menopausal Women, Arch Osteoporos, vol.13, issue.1, p.33, 2018. ,
, New Symmetrically Esterified M-Bromobenzyl Non-Aminobisphosphonates Inhibited Breast Cancer Growth and Metastases, vol.4, p.4685, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00416602
Structure-Activity Relationships of a New Class of Aromatic Bisphosphonates That Inhibit Tumor Cell Proliferation In Vitro, Anticancer Res, vol.25, issue.2A, pp.1139-1145, 2005. ,
The Influence of Pyrophosphate Analogues (Diphosphonates) on the Precipitation and Dissolution, Calcif. Tissue Res, vol.2, pp.10-10, 1968. ,
Structural Requirements for Bisphosphonate Actions in Vitro, J. Bone Miner. Res, vol.9, issue.12, pp.1875-1882, 1994. ,
Dissociation of Binding and Antiresorptive Properties of Hydroxybisphosphonates by Substitution of the Hydroxyl with an Amino Group, J. Bone Miner. Res, vol.11, issue.10, pp.1492-1497, 1996. ,
Method for Synthesizing Hydroxy-Bisphosphonic Acid Derivatives, International Patent Application WO, 2009. ,
Synthesis and In Vitro Characterization of Carboxymethyl Chitosan-CBA-Doxorubicin Conjugate Nanoparticles as pH-Sensitive Drug Delivery Systems, J. Biomed. Nanotechnol, vol.13, p.1097, 2017. ,
Self-Assembled Hyaluronic Acid Nanoparticles for pH-Sensitive Release of Doxorubicin: Synthesis and In Vitro Characterization, J. Biomed. Nanotechnol, vol.13, p.1058, 2017. ,
PH-Sensitive Nanosystem Based on Carboxymethyl Chitosan for Tumor-Targeted Delivery of Daunorubicin, J. Biomed. Nanotechnol, vol.12, issue.8, pp.1688-1698, 2016. ,
Redox Sensitive Shell and Core Crosslinked Hyaluronic Acid Nanocarriers for Tumor-Targeted Drug Delivery, J. Biomed. Nanotechnol, vol.12, issue.8, pp.1641-1653, 2016. ,
Near IR Fluorescent Conjugated Poly-(Ethylene Glycol)Bisphosphonate Nanoparticles for in Vivo Bone Targeting in a Young Mouse Model, J. Nanobiotechnol, vol.13, 2015. ,
Targeted Drug Delivery of near IR Fluorescent Doxorubicin-Conjugated Poly(Ethylene Glycol) Bisphosphonate Nanoparticles for Diagnosis and Therapy of Primary and Metastatic Bone Cancer in a Mouse Model, J. Nanobiotechnol, vol.14, 2016. ,
Bisphosphonate Conjugation for Bone Specific Drug Targeting, Bone Rep, vol.9, pp.47-60, 2018. ,
Targeting Therapeutics to Bone by Conjugation with Bisphosphonates, Curr. Opin. Pharmacol, vol.40, pp.87-94, 2018. ,
Osteotropic Therapy via Targeted Layer-by-Layer Nanoparticles, Adv. Healthcare Mater, vol.3, issue.6, pp.867-875, 2014. ,
First-in-Human Phase I Study of MBC-11, a Novel Bone-Targeted Cytarabine-Etidronate Conjugate in Patients with Cancer-Induced Bone Disease, Oncologist, vol.24, p.303, 2019. ,
, , 2015.
, Bone Metastases by a PH-Sensitive Conjugation, J. Pharm. Sci, vol.104, issue.7, pp.2293-2303
Development of Novel Bisphosphonate Prodrugs of Doxorubicin for Targeting Bone Metastases That Are Cleaved PH Dependently or by Cathepsin B:Synthesis, Cleavage Properties, and Binding Properties to Hydroxyapatite As Well As Bone Matrix, J. Med. Chem, vol.55, issue.17, pp.7502-7515, 2012. ,
, International Patent WO2011023367A3
, , 2016.
, Hydrosoluble Hydroxy-Bisphosphonic Derivatives of Doxorubicin PCT Int. Appl. WO
Bifunctional Hydroxy-Bisphosphonic Acid Derivatives, PCT Int. Appl. WO, 2012. ,
Hydroxy-Bisphosphonic Acid Derivatives as Vectors for Therapeutic and Diagnostic Targeting of Bone Tissue, PCT Int. Appl. WO, 2009. ,
A One-Pot Synthesis of 1-Hydroxy-1,1-Bis(Phosphonic Acid)s Starting from the Corresponding Carboxylic Acids, Eur. J. Org. Chem, pp.7148-7154, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-02143149
A Mild and Efficient One-Pot Synthesis of 1-Hydroxymethylene-1,1-Bisphosphonic Acids. Preparation of New Tripod Ligands, Tetrahedron Lett, vol.42, p.8475, 2001. ,
Probe for the Measurement of Cell Surface PH in Vivo and Ex Vivo, Proc. Natl. Acad. Sci. U. S. A, vol.113, issue.29, pp.8177-8181, 2016. ,
Blood Flow, Oxygen and Nutrient Supply, and Metabolic Microenvironment of Human Tumors, Cancer Res, vol.49, issue.23, pp.6449-6465, 1989. ,
, , 1988.
, Microelectrode Studies on the Acid Microenvironment beneath Adherent Macrophages and Osteoclasts. Exp. Cell Res, vol.175, issue.2, pp.266-276
Doxorubicin Loaded Polymeric Nanoparticulate Delivery System to Overcome Drug Resistance in Osteosarcoma, BMC Cancer, vol.9, p.399, 2009. ,
Visualizing Mineral Binding and Uptake of Bisphosphonate by Osteoclasts and Non-Resorbing Cells, Bone, vol.42, issue.5, pp.848-860, 2008. ,
Endocytotic Uptake of Zoledronic Acid by Tubular Cells May Explain Its Renal Effects in Cancer Patients Receiving High Doses of the Compound, PLoS One, vol.10, issue.3, p.121861, 2015. ,
Cytosolic Entry of Bisphosphonate Drugs Requires Acidification of Vesicles after Fluid-Phase Endocytosis, Mol. Pharmacol, vol.69, issue.5, pp.1624-1632, 2006. ,
, Toxicol. Appl. Pharmacol, vol.79, issue.3, pp.412-422, 1985.
Acute and Repeat-Dose Toxicity Studies of the (6-Maleimidocaproyl)Hydrazone Derivative of Doxorubicin (DOXO-EMCH), an Albumin-Binding Prodrug of the Anticancer Agent Doxorubicin, Hum. Exp. Toxicol, vol.26, issue.1, pp.19-35, 2007. ,
Development of Doxorubicin-Induced Chronic Cardiotoxicity in the B6C3F1Mouse Model, Toxicol. Appl. Pharmacol, vol.266, issue.1, pp.109-121, 2013. ,
-Labelled Gemcitabine/Bisphosphonate (Gem/BP): A Multi-Functional, Bone-Specific Agent as a Potential Treatment for Bone Metastases, Eur. J. Nucl. Med. Mol. Imaging, vol.35, issue.7, pp.1240-1248, 2008. ,
(CO)3-Labeled Pamidronate and Alendronate for Bone Imaging, Dalton Trans, vol.40, issue.12, pp.2787-2796, 2011. ,
Design, Synthesis, and Pharmacokinetics of a Bone-Targeting Dual-Action Prodrug for the Treatment of Osteoporosis, J. Med. Chem, vol.60, issue.16, pp.7012-7028, 2017. ,
Randomised Trial of Two Regimens of Chemotherapy in Operable Osteosarcoma: A Study of the European Osteosarcoma Intergroup, Lancet, vol.350, issue.9082, pp.911-917, 1997. ,
An experimental model of osteosarcomas in rats, Sem Hop, vol.58, pp.1684-1689, 1982. ,